Nerlynx FDA Approval History
Nerlynx (neratinib) is a tyrosine kinase inhibitor indicated:
- as a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
- in combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
Development Timeline for Nerlynx
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.